ArticleBreast cancer research : BCR2026
Association between metabolic dysfunction-associated steatotic liver disease and breast cancer risk in Korean women: a nationwide population-based cohort study.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Breast Cancer and Metabolic Dysfunction-Associated Steatotic Liver Disease.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMetabolic dysfunction-associated steatotic liver disease (MASLD) is a common chronic liver disorder linked to systemic metabolic imbalance. Although MASLD has been associated with extrahepatic cancers, including breast cancer, evidence is limited, especially among Asian populations. Given the younger peak incidence of breast cancer in Korea, this study examined the association between MASLD and breast cancer risk in middle-aged Korean women.
methodsWe conducted a nationwide, population-based cohort study of 483,279 randomly selected Korean women aged 40–60 years who underwent health checkups from 2012 to 2015. MASLD was defined using the International Classification of Disease-10 (ICD-10) codes or a fatty liver index (FLI ≥ 60) with metabolic criteria. Breast cancer cases were identified using ICD-10 codes (C50, D05) and followed through 2021. Adjusted hazard ratios (HRs) were estimated with Cox proportional hazards models, including subgroup analyses by body mass index (BMI) and menopausal status.
resultsMASLD was not significantly linked to overall breast cancer risk (adjusted HR = 1.089, 95% CI 0.984–1.205, p = 0.099). However, women with BMI 25–30 kg/m² showed a significantly higher risk (adjusted HR = 1.077, p = 0.011). Although postmenopausal women had a lower overall risk, MASLD was significantly associated with increased risk in postmenopausal women with BMI 25–30 kg/m² (adjusted HR = 1.203, 95% CI 1.029–1.407, p = 0.021).
conclusionIn this large Korean cohort, MASLD was not independently linked to overall breast cancer risk, but moderate obesity and menopause may influence this relationship. These findings highlight the need to consider metabolic and hormonal factors in risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.